PRAA

The FY2025 GAAP net loss of -$305M and -$7.79 diluted EPS look alarming, but the MD&A is explicit that this is driven by a $412.6M non-cash goodwill impairment, partly offset by a $38.4M gain on sale of an equity-method investment. On an adjusted basis PRA earned $72.6M ($1.84 EPS), slightly ahead of 2024's $70.6M/$1.79. The underlying franchise is strengthening, not deteriorating: portfolio income — the stable yield component — rose 18.2%, ERC reached $8.6B (+15.4%), cash collections hit $2.1B (+13%), and the U.S. turnaround is real, with a ~40% cut to onshore agent headcount alongside a 19.8% jump in U.S. Core collections. Revenue of $1.20B (+7.8%) confirms the top line has recovered fully from the 2022-23 trough.

Valuation is the constructive part of the case. At $18.28 the market cap ($703M) sits well below stockholders' equity of $980M (~0.72x book), P/S is just 0.6x, and against adjusted EPS of $1.84 the stock trades near 10x earnings. For a cash-generative collector whose ERC backlog ($8.6B) is more than 12x annual revenue, that is not a demanding price — the market is pricing in the GAAP loss and leverage rather than the adjusted earnings power.